Rheumatoid arthritis
Conditions
Interventions
Experimental group:none
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patient age>= 18 years old; 2.Diagnosed by a doctor with rheumatoid arthritis, meeting the diagnostic criteria for RA classification formulated by ACR/EULAR in 2010; 3. RA disease activity (DAS28>=2.6); 4. No prior treatment with tocilizumab; 5.Good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Live vaccine immunization within 4 weeks prior to screening; 2.History of underlying tuberculosis infection or tumor; 3.acute or chronic active infection; 4.Accompanied by other diffuse connective tissue diseases such as systemic lupus erythematosus, severe knee osteoarthritis and Sjogren's syndrome; 5. Severe hepatic and renal insufficiency; 6.Severe heart, brain and vascular lesions; 7. Pregnant or lactating women; 8.Treatment with any biologic agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to initiation of tocilizumab therapy 9.Those who have mental disorders, a history of alcoholism, immunodeficiency, drug or other substance abuse; 10.Those who are allergic to the ingredients of this product; 11.Those who are judged by the investigator to be unable to comply with the requirements of the study or who withdraw voluntarily.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving ACR20 at week 24 after the first dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| 28 levels of joint disease activity;Clinical Disease Activity Index; | — |
Countries
China
Contacts
Public ContactQing Yufeng
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed